Optimal dose and safety of molnupiravir in patients with early sars-cov-2: a phase i, open-label, dose-escalating, randomized controlled study

HIGHLIGHTS

• who: J Antimicrob, Chemother and Contributed, equally. from the University of Liverpool, Pembroke Place, Liverpool, UK have published the Article: Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study, in the Journal: (JOURNAL) of 15/06/2021
• what: The authors report Phase Ib results where the authors sought to determine the safety and tolerability of multiple ascending doses of molnupiravir in participants with PCR-confirmed SARS-CoV-2 infection who had symptoms within the preceding 5 days, which did not require . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.